Smoking history as an independent predictor for immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Wang, Xinan [1 ]
Ricciuti, Biagio [2 ]
Alessi, Joao V. [2 ]
Nguyen, Tom [2 ]
Awad, Mark M. [2 ]
Lin, Xihong [3 ]
Johnson, Bruce E. [2 ]
Christiani, David C. [3 ]
机构：
[1] Harvard Grad Sch Arts & Sci, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao, V
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (12): : 1761 - 1769
  • [2] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Hopkins, Ashley M.
    Kichenadasse, Ganessan
    Logan, Jessica M.
    Rowland, Andrew
    Sorich, Michael J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 475 - 476
  • [3] Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
    Giustini, Nicholas
    Bazhenova, Lyudmila
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 21 - 34
  • [4] The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
    Hirsh, Vera
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [5] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer Response
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao, V
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 477 - 478
  • [6] Comprehensive genomic analysis with immunological parameters to obtain the biomarkers for immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
    Owada, Yuki
    Muto, Satoshi
    Takagi, Hironori
    Inoue, Takuya
    Watanabe, Yuzuru
    Yamaura, Takumi
    Fukuhara, Mitsuro
    Okabe, Naoyuki
    Matsumura, Yuki
    Hasegawa, Takeo
    Tanaka, Daisuke
    Ito, Emi
    Nanamiya, Hideaki
    Imai, Jun-ichi
    Isogai, Takao
    Watanabe, Shinya
    Suzuki, Hiroyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [7] Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS)
    Thompson, J.
    Arce-Lara, C.
    Menon, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S741 - S741
  • [8] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [9] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [10] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?
    Gargalionis, Antonios N.
    Papavassiliou, Kostas A.
    Papavassiliou, Athanasios G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
12345